| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H27Cl2FN2O6S |
| Molecular Weight | 609.493 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NC(=O)C1=CC(NS(=O)(=O)C2=C(Cl)C=C(C=C2)C3CC3)=C(OC4=CC(F)=C(CC(O)=O)C=C4Cl)C=C1
InChI
InChIKey=PFWVGKROPKKEDW-UHFFFAOYSA-N
InChI=1S/C28H27Cl2FN2O6S/c1-28(2,3)32-27(36)17-6-8-23(39-24-14-21(31)18(11-19(24)29)13-26(34)35)22(12-17)33-40(37,38)25-9-7-16(10-20(25)30)15-4-5-15/h6-12,14-15,33H,4-5,13H2,1-3H3,(H,32,36)(H,34,35)
| Molecular Formula | C28H27Cl2FN2O6S |
| Molecular Weight | 609.493 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Vidupiprant, also known as AMG 853, is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. Vidupiprant inhibits PGD2-induced down modulation of CRTH2 on CD16- granulocytes in human whole blood as well as PGD2-induced cAMP response in platelets. It inhibits PGD2-induced airway constriction in vivo. Also inhibits BRD4 (Kd = 170 nM). AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma. AMG 853 has been discontinued due to poor efficacy.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 3.0 nM [IC50] | |||
| 35.0 nM [IC50] |
PubMed
Patents
Sample Use Guides
Adults with moderate-to-severe asthma were randomized to placebo; 5, 25, or 100 mg of oral Vidupiprant (AMG 853) twice daily; or 200 mg of AMG 853 once daily for 12 weeks.
Route of Administration:
Oral
